Literature DB >> 3092731

In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

M D Lyon, K R Smith, M S Saag, G A Cloud, C G Cobbs.   

Abstract

A total of 103 isolates of Pseudomonas aeruginosa were studied to compare the in vitro effectiveness of three beta-lactam antibiotics (piperacillin, ticarcillin, and mezlocillin) when used alone and in combination with four aminoglycosides (tobramycin, gentamicin, amikacin, and netilmicin). All drugs were tested as single agents against a standard inoculum (5 X 10(5) CFU/ml). The three antipseudomonal penicillins were also tested against the isolates at a higher inoculum concentration (10(7) CFU/ml). Synergy testing was performed by the two-dimensional checkerboard method and was defined by a fractional bactericidal index of less than or equal to 0.5 and bacterial killing accomplished at antibiotic concentrations no greater than those achievable in serum. All combinations were assessed for synergy. The degree of synergy was further analyzed by dividing the isolates into groups based on their susceptibility and resistance to the individual agents in the combination. The overall effectiveness of the various aminoglycoside-antipseudomonal penicillin combinations was assessed regarding their ability to kill the isolates either as single agents or through synergy. Piperacillin was the most active antipseudomonal penicillin, and tobramycin and amikacin were the most active aminoglycosides when used as single agents. When tested against isolates at a higher inoculum concentration, ticarcillin was significantly more active than the other beta-lactams. The highest degree of overall synergy was noted with gentamicin-ticarcillin (78.2% of strains) and amikacin-piperacillin (77% of strains). When assessed for overall effectiveness, all combinations containing amikacin were the most active. The combination of amikacin-piperacillin was the most effective, with activity against 96% of all isolates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092731      PMCID: PMC176428          DOI: 10.1128/AAC.30.1.25

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides.

Authors:  A L Barry; C Thornsberry; R N Jones; T L Gavan
Journal:  Cleve Clin Q       Date:  1980

2.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

3.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

4.  Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease.

Authors:  M I Thompson; M E Russo; B J Saxon; E Atkin-Thor; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.

Authors:  T O Kurtz; D J Winston; D A Bruckner; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

7.  Comparative in vitro appraisal of piperacillin, including its activity against Salmonella typhi.

Authors:  R G Robinson; J Saunders; R Cassel; C S Block; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.

Authors:  M L Corrado; S H Landesman; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Piperacillin pharmacokinetics in subjects with chronic renal failure.

Authors:  M I Thompson; M E Russo; J M Matsen; E Atkin-Thor
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

10.  Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin.

Authors:  L K Pickering; I Rutherford
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

View more
  5 in total

Review 1.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 3.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

4.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.

Authors:  Janus Haagensen; Davide Verotta; Liusheng Huang; Joanne Engel; Alfred M Spormann; Katherine Yang
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.